| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Pierre-Michel Llorca | Q83120424 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| patient | Q181600 | ||
| P1104 | number of pages | 13 | |
| P304 | page(s) | 235-247 | |
| P577 | publication date | 2008-10-11 | |
| P1433 | published in | Psychiatry Research | Q15750888 |
| P1476 | title | Partial compliance in schizophrenia and the impact on patient outcomes | |
| P478 | volume | 161 |
| Q38067137 | A review of paliperidone palmitate |
| Q45246308 | Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. |
| Q47998008 | Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics |
| Q35579197 | An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia. |
| Q38611031 | Antipsychotic medication side effect assessment tools: A systematic review. |
| Q99552121 | Assessment of Real-Life Outcomes in Schizophrenia Patients according to Compliance |
| Q36817257 | Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus |
| Q38425149 | Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center |
| Q47138380 | Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice |
| Q50867891 | Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain. |
| Q38287203 | Depot-medication compliance for patients with psychotic disorders: the importance of illness insight and treatment motivation. |
| Q37807738 | Diagnostic stability of first-episode psychosis and predictors of diagnostic shift from non-affective psychosis to bipolar disorder: A retrospective evaluation after recurrence |
| Q35186503 | Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia |
| Q47618934 | Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice |
| Q36555362 | Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis |
| Q47225222 | Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates |
| Q34286350 | Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data |
| Q36211694 | Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone? |
| Q43260838 | Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study |
| Q40309621 | Exploratory analysis of the French version of the beliefs about medicines questionnaire in patients with severe mental disorders: Factorial structure and reliability in specific populations of schizophrenic, bipolar and depressive patients |
| Q57602650 | Factors associated with relapse in patients with schizophrenia |
| Q50755546 | Financial impact of a pharmacist-managed clinic for long-acting injectable antipsychotics. |
| Q38942444 | Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial |
| Q87234183 | Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage |
| Q38071595 | Improving treatment adherence in your patients with schizophrenia: the STAY initiative |
| Q86748193 | Inadequate management of medicines by the older-aged living in a retirement village |
| Q42624241 | Influencing factors of community mental health nurses caring for people with schizophrenia in Taiwan |
| Q42657327 | Intervening conditions of hospital-based home care for people with severe mental illness |
| Q37778398 | Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review |
| Q40512185 | Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone |
| Q37248065 | Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review |
| Q47992912 | Mental health nurses' views about antipsychotic medication side effects |
| Q37580919 | Mobile phone text message reminders of antipsychotic medication: is it time and who should receive them? A cross-sectional trust-wide survey of psychiatric inpatients |
| Q34650576 | Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders |
| Q38086645 | Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment |
| Q44732992 | Optimizing treatment of schizophrenia to minimize relapse |
| Q38989642 | Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation |
| Q42252223 | Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection |
| Q51811452 | Patient's trust in their psychiatrist: a cross-sectional survey. |
| Q36927085 | Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders |
| Q28084899 | Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review |
| Q36587739 | Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa |
| Q37104411 | Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey |
| Q34459567 | Quantitative levels of aripiprazole parent drug and metabolites in urine |
| Q34660553 | Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial |
| Q34746791 | Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada |
| Q43107442 | Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients |
| Q40488575 | Schizophrenia: Impact of psychopathology, faith healers and psycho-education on adherence to medications |
| Q40043812 | Stigma and higher rates of psychiatric re-hospitalization: São Paulo public mental health system |
| Q50263295 | Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the New Medicine Service. |
| Q37547469 | Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study |
| Q55009590 | The effect of financial incentives on patients' motivation for treatment: results of "Money for Medication," a randomised controlled trial. |
| Q35021287 | The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population |
| Q38462579 | The influence of therapeutic alliance and insight on medication adherence in schizophrenia |
| Q39263968 | Through the Looking Glass: Estimating Effects of Medical Homes for People with Severe Mental Illness |
| Q40525039 | Trauma and post-traumatic stress disorder in schizophrenia |
| Q97587444 | Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine |
| Q37079066 | Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study |
Search more.